|
1.
|
Alavian SM, Tabatabaei SV, Keshvari M, et
al: Peginterferon alpha-2a and ribavirin treatment of patients with
haemophilia and hepatitis C virus infection: a single-centre study
of 367 cases. Liver Int. 30:1173–1180. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Welzel TM, Morgan TR, Bonkovsky HL, et al:
Variants in interferon-alpha pathway genes and response to
pegylated interferon-alpha2a plus ribavirin for treatment of
chronic hepatitis C virus infection in the hepatitis C antiviral
long-term treatment against cirrhosis trial. Hepatology.
49:1847–1858. 2009. View Article : Google Scholar
|
|
3.
|
Kurosaki M, Tanaka Y, Nishida N, et al:
Pre-treatment prediction of response to pegylated-interferon plus
ribavirin for chronic hepatitis C using genetic polymorphism in
IL28B and viral factors. J Hepatol. 54:439–448. 2011. View Article : Google Scholar
|
|
4.
|
Yasui K, Harano Y, Mitsuyoshi H, et al:
Steatosis and hepatic expression of genes regulating lipid
metabolism in Japanese patients infected with hepatitis C virus. J
Gastroenterol. 45:95–104. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Ochi H, Maekawa T, Abe H, et al: IL-28B
predicts response to chronic hepatitis C therapy-fine-mapping and
replication study in Asian populations. J Gen Virol. Jan. 12–2011,
(E-pub ahead of print).
|
|
6.
|
Hadziyannis SJ and Koskinas JS:
Differences in epidemiology, liver disease and treatment response
among HCV genotypes. Hepatol Res. 29:129–135. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Hadziyannis SJ, Sette H Jr, Morgan TR, et
al: Peginterferon-alpha2a and ribavirin combination therapy in
chronic hepatitis C: a randomized study of treatment duration and
ribavirin dose. Ann Intern Med. 140:346–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Iino S, Ichida F, Sakuma A and Suzuki H: A
randomized clinical trial with natural interferon-alpha monotherapy
for 24 or 48 weeks in patients with chronic hepatitis C having
genotype 1b infection in high viral titers. Hepatol Res.
24:338–345. 2002. View Article : Google Scholar
|
|
9.
|
Enomoto N, Sakuma I, Asahina Y, et al:
Mutations in the nonstructural protein 5A gene and response to
interferon in patients with chronic hepatitis C virus 1b infection.
N Engl J Med. 334:77–81. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Akuta N, Suzuki F, Kawamura Y, et al:
Predictors of viral kinetics to peginterferon plus ribavirin
combination therapy in Japanese patients infected with hepatitis C
virus genotype 1b. J Med Virol. 79:1686–1695. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Izumi N, Asahina Y and Kurosaki M:
Predictors of virological response to a combination therapy with
pegylated interferon plus ribavirin including virus and host
factors. Hepat Res Treat. 2010:7036022010.PubMed/NCBI
|
|
12.
|
Tanaka Y, Nishida N, Sugiyama M, et al:
Genome-wide association of IL28B with response to pegylated
interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat
Genet. 41:1105–1109. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Ge D, Fellay J, Thompson AJ, et al:
Genetic variation in IL28B predicts hepatitis C treatment-induced
viral clearance. Nature. 461:399–401. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Livak KJ: Allelic discrimination using
fluorogenic probes and the 5′ nuclease assay. Genet Anal.
14:143–149. 1999.
|
|
15.
|
Marcello T, Grakoui A, Barba-Spaeth G, et
al: Interferons alpha and lambda inhibit hepatitis C virus
replication with distinct signal transduction and gene regulation
kinetics. Gastroenterology. 131:1887–1898. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Charlton MR, Pockros PJ and Harrison SA:
Impact of obesity on treatment of chronic hepatitis C. Hepatology.
43:1177–1186. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Tsubota A, Fujise K, Namiki Y and Tada N:
Peginterferon and ribavirin treatment for hepatitis C virus
infection. World J Gastroenterol. 17:419–432. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
McHutchison JG, Lawitz EJ, Shiffman ML, et
al: Peginterferon alpha-2b or alpha-2a with ribavirin for treatment
of hepatitis C infection. N Engl J Med. 361:580–593. 2009.
View Article : Google Scholar : PubMed/NCBI
|
